Established in 2017, the Corrona MS Registry is a real-world U.S.-based registry, developed in collaboration with the National MS Society. Its goal is to help guide treatment decisions based on real-world effectiveness and safety analyses. Through questionnaires, physician assessments, and patient-reported outcomes, Corrona’s team of biostatisticians and epidemiologists will study the relative safety and effectiveness of approved MS therapies.
To date, the MS Registry has enrolled more than 700 patients. The registry, which gathers clinical data from patients and their neurologists, eventually hopes to recruit up to 5,000 MS participants.
Corrona’s collaborative model includes working alongside pharmaceutical companies to quickly scale registries that benefit all stakeholders. The Cambridge, Massachusetts-based company operates six other disease registries across the U.S., Canada, and Japan.
“We envision that the collaborative registry model will continue to build momentum in the U.S., particularly for many autoimmune diseases where patient-reported outcomes and detailed clinical assessments remain the gold standard for studying real-world drug effectiveness,” Jeff Greenberg, MD, Corrona’s chief medical officer, said in a press release.
According to Bruce Bebo, PhD, executive vice president, research at the National MS Society, “The comprehensive, high-quality observational data generated by the registry will bridge the evidence gap in MS research and provide the real-world context needed to make informed treatment decisions.”
Daniel Kantor, MD, registry co-director and director of neurology at Florida Atlantic University’s Charles E. Schmidt College of Medicine, said the registry is uniquely positioned to help advance clinical research and improve patient care for the whole MS community, including patients and their healthcare providers.
As with Corrona’s other registries, the MS effort aggregates specific information, including past and current medications, whether a patient has multiple chronic conditions, clinical measures of drug effectiveness, any adverse events (side effects), and patient-reported outcomes.
“As a neurologist treating MS patients, reviewing data from an independent registry like Corrona can provide valuable insight into the impact of treatments on clinical outcomes and quality of life for MS patients,” said Aaron Miller, MD, registry scientific co-director and professor of neurology at the Icahn School of Medicine at Mount Sinai in New York City.
Visit this site to learn how to participate in the registry as a neurologist or patient.